|
|
Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
Sources News Release
http://www.sources.com/Releases/NR943.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 10/08/2010
Year Published: 2010
Resource Type: Article
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
Abstract: CALIFON, NJ, BASEL, Switzerland and DRESDEN, Germany # August 10, 2010 - Anavex Life Sciences Corp. (#ANAVEX#) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (#Genesis#) and ABX-CRO Advanced Pharmaceutical Services (#ABX-CRO#) to begin clinical studies and regulatory filings for ANAVEX 2-73, its lead compound for the treatment of Alzheimer#s Disease.
#Selecting Genesis and ABX-CRO to advance ANAVEX 2-73 to the clinical r...
To read the full release go to http://www.sources.com/Releases/NR943.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
